France · Delayed Price · Currency is EUR Biosynex Statistics
Total Valuation
Biosynex has a market cap or net worth of EUR 15.30 million. The enterprise value is 68.84 million.
| Market Cap | 15.30M |
| Enterprise Value | 68.84M |
Important Dates
The next estimated earnings date is Friday, April 30, 2027.
| Earnings Date | Apr 30, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
Biosynex has 18.43 million shares outstanding. The number of shares has increased by 27.99% in one year.
| Current Share Class | 18.43M |
| Shares Outstanding | 18.43M |
| Shares Change (YoY) | +27.99% |
| Shares Change (QoQ) | -3.48% |
| Owned by Insiders (%) | 6.56% |
| Owned by Institutions (%) | n/a |
| Float | 7.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.17 |
| PB Ratio | 0.49 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.77 |
| EV / EBITDA | n/a |
| EV / EBIT | 5.60 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.26, with a Debt / Equity ratio of 2.00.
| Current Ratio | 3.26 |
| Quick Ratio | 2.12 |
| Debt / Equity | 2.00 |
| Debt / EBITDA | 30.62 |
| Debt / FCF | n/a |
| Interest Coverage | 2.80 |
Financial Efficiency
Return on equity (ROE) is -34.68% and return on invested capital (ROIC) is 14.63%.
| Return on Equity (ROE) | -34.68% |
| Return on Assets (ROA) | 5.54% |
| Return on Invested Capital (ROIC) | 14.63% |
| Return on Capital Employed (ROCE) | 10.92% |
| Weighted Average Cost of Capital (WACC) | 6.36% |
| Revenue Per Employee | 226,403 |
| Profits Per Employee | -34,738 |
| Employee Count | 397 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 1.82 |
Taxes
In the past 12 months, Biosynex has paid 637,000 in taxes.
| Income Tax | 637,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +53.70% in the last 52 weeks. The beta is 0.97, so Biosynex's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | +53.70% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 0.91 |
| Relative Strength Index (RSI) | 46.82 |
| Average Volume (20 Days) | 24,392 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biosynex had revenue of EUR 89.88 million and -13.79 million in losses. Loss per share was -0.73.
| Revenue | 89.88M |
| Gross Profit | 48.18M |
| Operating Income | 12.44M |
| Pretax Income | -13.15M |
| Net Income | -13.79M |
| EBITDA | 2.05M |
| EBIT | 12.44M |
| Loss Per Share | -0.73 |
Balance Sheet
The company has 9.32 million in cash and 62.86 million in debt, with a net cash position of -53.54 million or -2.90 per share.
| Cash & Cash Equivalents | 9.32M |
| Total Debt | 62.86M |
| Net Cash | -53.54M |
| Net Cash Per Share | -2.90 |
| Equity (Book Value) | 31.49M |
| Book Value Per Share | 1.67 |
| Working Capital | 39.63M |
Cash Flow
In the last 12 months, operating cash flow was -2.62 million and capital expenditures -2.28 million, giving a free cash flow of -4.90 million.
| Operating Cash Flow | -2.62M |
| Capital Expenditures | -2.28M |
| Depreciation & Amortization | -10.38M |
| Net Borrowing | -802,000 |
| Free Cash Flow | -4.90M |
| FCF Per Share | -0.27 |
Margins
Gross margin is 53.60%, with operating and profit margins of 13.84% and -15.34%.
| Gross Margin | 53.60% |
| Operating Margin | 13.84% |
| Pretax Margin | -14.63% |
| Profit Margin | -15.34% |
| EBITDA Margin | 2.28% |
| EBIT Margin | 13.84% |
| FCF Margin | n/a |
Dividends & Yields
Biosynex does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -27.99% |
| Shareholder Yield | -27.99% |
| Earnings Yield | -88.08% |
| FCF Yield | -32.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |